Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
1.140
-0.080 (-6.56%)
At close: Dec 5, 2025, 4:00 PM EST
1.120
-0.020 (-1.75%)
After-hours: Dec 5, 2025, 7:40 PM EST
Jupiter Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
39.25M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
JUNS News
- 3 days ago - Jupiter Neurosciences to Participate in NobleCon21 - Newsfile Corp
- 5 weeks ago - Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing - GlobeNewsWire
- 3 months ago - Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador - GlobeNewsWire
- 4 months ago - Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - GlobeNewsWire
- 5 months ago - Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 5 months ago - Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery - GlobeNewsWire
- 5 months ago - Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador - GlobeNewsWire
- 10 months ago - Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - GlobeNewsWire